{'52WeekChange': 0.061538458,
 'SandP52WeekChange': 0.0644362,
 'address1': 'No. 3 Yuanqu Street',
 'address2': '11th Floor-1 Nangang District',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 5.55,
 'askSize': 1000,
 'averageDailyVolume10Day': 259387,
 'averageVolume': 39307,
 'averageVolume10days': 259387,
 'beta': 0.97729,
 'beta3Year': None,
 'bid': 5.51,
 'bidSize': 1000,
 'bookValue': 0.24,
 'category': None,
 'circulatingSupply': None,
 'city': 'Taipei',
 'companyOfficers': [],
 'country': 'Taiwan',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 5.78,
 'dayLow': 5.33,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 204728512,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 5.831714,
 'fiftyTwoWeekHigh': 12.65,
 'fiftyTwoWeekLow': 2.48,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 29704921,
 'forwardEps': -0.58,
 'forwardPE': -9.5172415,
 'fromCurrency': None,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0,
 'heldPercentInstitutions': 0.01788,
 'industry': '',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/tlcbio.com',
 'longBusinessSummary': 'Taiwan Liposome Company, Ltd., a clinical-stage '
                        'specialty pharmaceutical company, engages in the '
                        'development and commercialization of nanomedicines '
                        'that combine its proprietary lipid-assembled drug '
                        'delivery platform with approved active pharmaceutical '
                        'ingredients (APIs). Its BioSeizer lipid formulation '
                        'technology enables pharmacokinetic (PK) control and '
                        'local sustained release of APIs at the site of '
                        'disease or injury; and NanoX active drug loading '
                        'technology enables the potential for reduced dosing '
                        'frequency and enhanced distribution of '
                        'liposome-encapsulated APIs to the desired site. The '
                        'company provides various product candidates that '
                        'target various areas of unmet medical need in pain '
                        'management, ophthalmology, and oncology. Its lead '
                        'product candidate is TLC599, an intraarticular '
                        'injectable BioSeizer formulation of the API steroid '
                        'dexamethasone sodium phosphate (DSP), which is in '
                        'Phase III trial for knee osteoarthritis pain. The '
                        "company's product candidates also comprises TLC590, a "
                        'non-opioid BioSeizer formulation of the API '
                        'ropivacaine that is in Phase II clinical trial for '
                        'post-surgical pain management; TLC399, a '
                        'multilamellar and multivesicular BioSeizer '
                        'formulation of DSP, which is in Phase II clinical '
                        'trial for ophthalmology indications; and TLC178, an '
                        'API that is in Phase I/II dose escalation trial to '
                        'treat rhabdomyosarcoma. Taiwan Liposome Company, Ltd. '
                        'was founded in 1997 and is headquartered in Taipei, '
                        'Taiwan.',
 'longName': 'Taiwan Liposome Company, Ltd.',
 'market': 'us_market',
 'marketCap': 249553680,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_46504690',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 5.78,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '886 2 2655 7377',
 'previousClose': 5.46,
 'priceHint': 2,
 'priceToBook': 23,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 5.78,
 'regularMarketDayLow': 5.33,
 'regularMarketOpen': 5.78,
 'regularMarketPreviousClose': 5.46,
 'regularMarketPrice': 5.78,
 'regularMarketVolume': 20271,
 'revenueQuarterlyGrowth': None,
 'sector': '',
 'sharesOutstanding': 42094500,
 'sharesPercentSharesOut': 0.0001,
 'sharesShort': 1121,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3242,
 'shortName': 'Taiwan Liposome Company, Ltd.',
 'shortPercentOfFloat': None,
 'shortRatio': 0.24,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'TLC',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.506,
 'twoHundredDayAverage': 4.9845324,
 'volume': 20271,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.tlcbio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '11503'}